Literature DB >> 1867957

Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine.

Q Y Yue1, J Hasselström, J O Svensson, J Säwe.   

Abstract

1. The kinetics of codeine and seven of its metabolites codeine-6-glucuronide (C6G), norcodeine (NC), NC-glucuronide (NCG), morphine (M), M-3 (M3G) and 6-glucuronides (M6G), and normorphine (NM) were investigated after a single oral dose of 50 mg codeine phosphate in 14 healthy Caucasian subjects including eight extensive (EM) and six poor (PM) hydroxylators of debrisoquine. The plasma and urine concentrations of codeine and the metabolites were measured by h.p.l.c. 2. The mean area under the curve (AUC), half-life and total plasma clearance of codeine were 1020 +/- 340 nmol l-1 h, 2.58 +/- 0.57 h and 2.02 +/- 0.73 l h-1 kg-1, respectively. There were no significant differences between EM and PM in these aspects. 3. PM had significantly lower AUC of M3G, the active metabolites M6G, NM and M (P less than 0.0001), and lower partial metabolic clearance by O-demethylation (P less than 0.0001). In contrast, the PM had higher AUC of NC (P less than 0.05) than the EM. There was no difference between PM and EM in the AUC of C6G and NCG, nor in the partial clearances by N-demethylation and glucuronidation. 4. Among EM, the AUC of C6G was 15 times higher than that of codeine, which in turn was 50 times higher than that of M. The AUCs of M6G and NM were about 6 and 10 times higher than that of M, respectively. The partial clearance by glucuronidation was about 8 and 12 times higher than those by N- and O-demethylations, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1867957      PMCID: PMC1368572          DOI: 10.1111/j.1365-2125.1991.tb05585.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  32 in total

1.  Analgesic potency of normorphine in patients with postoperative pain.

Authors:  L LASAGNA; T J DE KORNFELD
Journal:  J Pharmacol Exp Ther       Date:  1958-11       Impact factor: 4.030

2.  The effect of N-demethylation on certain pharmacologic actions of morphine, codeine, and meperidine in the mouse.

Authors:  J W MILLER; H H ANDERSON
Journal:  J Pharmacol Exp Ther       Date:  1954-10       Impact factor: 4.030

3.  Clinical significance of the sparteine/debrisoquine oxidation polymorphism.

Authors:  K Brøsen; L F Gram
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

4.  Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease.

Authors:  D R Guay; W M Awni; J W Findlay; C E Halstenson; P A Abraham; J A Opsahl; E C Jones; G R Matzke
Journal:  Clin Pharmacol Ther       Date:  1988-01       Impact factor: 6.875

5.  Polymorphic debrisoquin hydroxylation in 757 Swedish subjects.

Authors:  E Steiner; L Bertilsson; J Säwe; I Bertling; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1988-10       Impact factor: 6.875

6.  Oral administration of codeine in the presence of ethanol: a pharmacokinetic study in man.

Authors:  E Bodd; K M Beylich; A S Christophersen; J Mørland
Journal:  Pharmacol Toxicol       Date:  1987-11

7.  Morphine-6-glucuronide, an important metabolite.

Authors:  S P Joel; R J Osborne; N S Nixon; M L Slevin
Journal:  Lancet       Date:  1985-05-11       Impact factor: 79.321

8.  Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI).

Authors:  P Dayer; J Desmeules; T Leemann; R Striberni
Journal:  Biochem Biophys Res Commun       Date:  1988-04-15       Impact factor: 3.575

9.  Morphine-6-glucuronide: analgesic effects and receptor binding profile in rats.

Authors:  F V Abbott; R M Palmour
Journal:  Life Sci       Date:  1988       Impact factor: 5.037

Review 10.  High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment.

Authors:  J Säwe
Journal:  Clin Pharmacokinet       Date:  1986 Mar-Apr       Impact factor: 6.447

View more
  30 in total

Review 1.  Analgesics and breast-feeding: safety considerations.

Authors:  O Spigset; S Hägg
Journal:  Paediatr Drugs       Date:  2000 May-Jun       Impact factor: 3.022

Review 2.  [Personalized drug therapy based on genetics. Possibilities and examples from clinical practice].

Authors:  J C Stingl; K S Just; K Kaumanns; M Schurig-Urbaniak; C Scholl; D von Mallek; J Brockmöller
Journal:  Internist (Berl)       Date:  2016-03       Impact factor: 0.743

3.  Analgesic and immunomodulatory effects of codeine and codeine 6-glucuronide.

Authors:  V Srinivasan; D Wielbo; J Simpkins; J Karlix; K Sloan; I Tebbett
Journal:  Pharm Res       Date:  1996-02       Impact factor: 4.200

Review 4.  Role of active metabolites in the use of opioids.

Authors:  Janet K Coller; Lona L Christrup; Andrew A Somogyi
Journal:  Eur J Clin Pharmacol       Date:  2008-10-29       Impact factor: 2.953

5.  Application of Model Informed Precision Dosing to Address the Impact of Pregnancy Stage and CYP2D6 Phenotype on Foetal Morphine Exposure.

Authors:  Sarah Badaoui; Ashley M Hopkins; A David Rodrigues; John O Miners; Michael J Sorich; Andrew Rowland
Journal:  AAPS J       Date:  2021-01-06       Impact factor: 4.009

6.  Influence of the CYP2D6 polymorphism and hemodialysis on codeine disposition in patients with end-stage renal disease.

Authors:  Hadi Molanaei; Juan Jesus Carrero; Olof Heimbürger; Louise Nordfors; Bengt Lindholm; Peter Stenvinkel; Ingegerd Odar-Cederlöf; Leif Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  2009-11-26       Impact factor: 2.953

Review 7.  Pharmacokinetic interactions with rifampicin : clinical relevance.

Authors:  Mikko Niemi; Janne T Backman; Martin F Fromm; Pertti J Neuvonen; Kari T Kivistö
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

8.  Pharmacokinetic-pharmacodynamic modeling of the miotic effects of dihydrocodeine in humans.

Authors:  Helmut Schmidt; Jörn Lötsch
Journal:  Eur J Clin Pharmacol       Date:  2007-09-05       Impact factor: 2.953

9.  CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.

Authors:  Mark R Hutchinson; Andrew Menelaou; David J R Foster; Janet K Coller; Andrew A Somogyi
Journal:  Br J Clin Pharmacol       Date:  2004-03       Impact factor: 4.335

10.  A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine.

Authors:  Q Y Yue; J O Svensson; F Sjöqvist; J Säwe
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.